Ser372
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser372  -  PARP1 (human)

Site Information
VAAtPPPstAsAPAA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 463804

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 ) , mutation of modification site ( 3 )
Disease tissue studied:
liver cancer ( 2 ) , hepatocellular carcinoma ( 2 )
Relevant cell line - cell type - tissue:
hepatocyte-liver ( 2 ) , MEF (fibroblast) [IGF1R (mouse)] ( 3 )

Upstream Regulation
Putative in vivo kinases:
ERK2 (human) ( 3 )
Treatments:
PD98059 ( 3 )

Downstream Regulation
Effects of modification on PARP1:
enzymatic activity, induced ( 3 )

References 

1

Kauppinen TM, Gan L, Swanson RA (2013) Poly(ADP-ribose) polymerase-1-induced NAD(+) depletion promotes nuclear factor-κB transcriptional activity by preventing p65 de-acetylation. Biochim Biophys Acta 1833, 1985-91
23597856   Curated Info

2

Gu T (2008) CST Curation Set: 4855; Year: 2008; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Kauppinen TM, et al. (2006) Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2. Proc Natl Acad Sci U S A 103, 7136-41
16627622   Curated Info